Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer

Psoriasis is a chronic relapsing immunoinflammatory dermatosis that is commonly associated with systemic comorbidities. The pathogenic importance of interleukin (IL)-12 and IL-23 is beyond doubt, as well as the involvement of T helper cells (Th)1 and Th17 cells. There is upregulation of the p40 subu...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2012-01, Vol.2012 (2012), p.1-5
Main Authors: Delvenne, Philippe, Humbert, Philippe, Piérard, Gérald E., Hermanns-Lê, Trinh, Quatresooz, Pascale, Piérard-Franchimont, Claudine
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Cytokines
Dermatologie
Dermatology
Disease
Helper cells
Hospitals
Human health sciences
Humans
Immune system
Interleukin-12 - immunology
Interleukin-23 - immunology
Pathogenesis
Psoriasis
Psoriasis - drug therapy
Psoriasis - immunology
Review
Sciences de la santé humaine
Skin diseases
Th17 Cells - immunology
Ustekinumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Psoriasis is a chronic relapsing immunoinflammatory dermatosis that is commonly associated with systemic comorbidities. The pathogenic importance of interleukin (IL)-12 and IL-23 is beyond doubt, as well as the involvement of T helper cells (Th)1 and Th17 cells. There is upregulation of the p40 subunit shared by IL-12 and IL-23 and of the IL-23 p19 subunit, but not an increased expression of the IL-12 p35 subunit. This indicates that IL-23 appears more involved than IL-12 in the pathogenesis of psoriatic plaques. Ustekinumab is a fully human monoclonal antibody of the immunoglobulin (Ig) G1 class targeting the p40 subunit common to both IL-12 and IL-23, thus inhibiting both IL-12 and IL-23 receptor-mediated signalling. Ustekinumab is part of the recent biologic therapies active in psoriasis, autoimmune arthritides, and inflammatory bowel diseases.
ISSN:2314-6133
1110-7243
1110-7251
2314-6141
1110-7251
DOI:10.1155/2012/147413